EP1086250A2 - Acides nucleiques - Google Patents

Acides nucleiques

Info

Publication number
EP1086250A2
EP1086250A2 EP99939503A EP99939503A EP1086250A2 EP 1086250 A2 EP1086250 A2 EP 1086250A2 EP 99939503 A EP99939503 A EP 99939503A EP 99939503 A EP99939503 A EP 99939503A EP 1086250 A2 EP1086250 A2 EP 1086250A2
Authority
EP
European Patent Office
Prior art keywords
sequences
primers
sense strand
linker
complementary
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP99939503A
Other languages
German (de)
English (en)
Inventor
Andrew Wallace
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Central Manchester Healthcare NHS Trust
Original Assignee
Central Manchester Healthcare NHS Trust
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Central Manchester Healthcare NHS Trust filed Critical Central Manchester Healthcare NHS Trust
Publication of EP1086250A2 publication Critical patent/EP1086250A2/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C12Q1/6853—Nucleic acid amplification reactions using modified primers or templates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1093—General methods of preparing gene libraries, not provided for in other subgroups
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6811—Selection methods for production or design of target specific oligonucleotides or binding molecules

Definitions

  • the present invention relates to a method of producing a DNA hybrid molecule comprised of a contiguous linear array of three or more sequences of interest (or potential interest) in predetermined relationship to each other.
  • a further application in which it may be desirable to provide a DNA hybrid molecule is DNA sequencing.
  • the amplified gene fragments from the separate PCR reactions are then purified, combined together and subjected to cycles of denaturing, reannealing and strand synthesis. As a result of these cycles, the complementary linker sequences hybridise to each other and are extended to produce a double stranded molecules which comprise the two gene fragments connected by the linker sequences.
  • the Gene splicing by overlap extension method requires fragments to b joined in a pairwise fashion thus including additional laborious steps of purification and re- amplification for the creation of constructs of more than two fragments. Furthermore, although the Gene Fusion method utilises Taq polymerase no account is taken in the primer design of the 3' dA overhangs introduced by Taq. Consequently with the primer design employed in US-A-5 023 171, the majority of fragments will have 3' mismatches leading to inefficient fusion of the two fragments.
  • a further technique for producing DNA hybride molecules is Gene Fusion as disclosed in Nucleic Acids Research, 17, 4895, (1989) (Yon & Freide) where a single linking primer is used to fuse the fragments. This is unlikely to be at all efficient for the fusion of more than two fragments since the PCR products themselves act as substitutes for primers for the whole of the fusion reaction leading to inefficient intermediate formation. Also with this published technique with only two fragments there is contamination by unfused products within the reaction.
  • WO- A-9215678 (Stratagene) which describes a PCR-based process for generating a library of dicistronic DNA molecules (comprising upstream and downstream cistrons) for producing antibodies.
  • the disclosure contemplates combining, in a single reaction vessel, (i) a repertoire of first polypeptide genes with a PCR primer pair therefor, one of the primers having a first 5 '-terminal non-priming portion providing a linking sequence; and
  • the first and second 5'-terminal portions are such that they are capable of hybridising to form a duplex encoding a double-stranded cistronic bridge for linking the upstream and downstream cistrons.
  • the library of dicistronic molecules is generated.
  • each of the first and second stage PCR reactions employs Taq as a thermostable polymerising enzyme.
  • those primers having linker sequences are designed such that their linker sequence is connected to their respective priming sequence via an adenosine residue. This takes account of the 3' adenine overhang added by Taq at the 3' end of an extended strand.
  • Primers incorporating the extra adenosine residue may of course be used both in conjunction with any other polymerising enzyme which adds a 3'-adenosine overhang at the end of an extended strand and those which do not.
  • thermostable polymerase which may or may not add a 3' adenine overhang to the end of an extended strand.
  • the invention enables a DNA hybrid molecule comprised of the sequences x,, x 2 x n (and their respective complements x,', x 2 ' x ⁇ ') in predetermined linked relationship to be produced in high yield from the respective individual sequences provided at diverse regions of the same or different DNA molecules.
  • the linker sequences which are used are independent of the sequences which are to be assembled into the intended hybrid molecule. Furthermore the incorporation of the additional adenosine residue for primers to be used in conjunction with Taq as the polymerising enzyme avoids 3' mismatches leading to inefficient fusion of fragments.
  • sequences x, x 2 x n may for example be exons which are separated by any distance (possibly of unknown sequence) along a particular DNA molecule whereas in the hybrid molecule produced by the method of the invention the sequences are spaced from each other by a relatively short, and known, sequence of, say, 20 to 30 bases.
  • Hybrid molecules produced in accordance with the method of the invention may for example be constructed for the purposes of mutation detection. More particularly, the hybrid molecule may comprise a plurality of exons (in which one or more mutations may be present) in a molecule having a length of up to 1.5 kb thus permitting mutation scanning of all of these exons using a technique such as CCM, EMC, NIRCA or PTT. A further possibility is a hybrid molecule comprised of a plurality of exons which may be constructed to enable more efficient sequencing of exons (as compared to their sequencing the exons at their locations in the endogenous DNA molecule).
  • a further possibility is that the method of the invention is used for the construction of hybrid genes.
  • the method of the invention involves two PCR reaction steps which allow the desired DNA hybrid molecule to be produced from the individual sequences xicide x 2 x n (and their complements x,', x 2 x n ) which are provided in a single reaction mixture. It will however be appreciated that, in certain circumstances, only one or other of the sets of complementary the sequences (x, x 2 x n ) or (x,' x 2 ' x-,') may initially be present at the start of the first PCR reaction, in which case the "missing" complementary sequences are generated in situ in the initial PCR reaction stage.
  • PCR primers for each set of complementary sequences (xicide x,'), (x 2 , x 2 ') (x n , x n ') which are to be present in the intended DNA hybrid molecule.
  • the primers hybridising to the 3' ends of the sequences x,' and x n may be "standard" PCR primers and may hybridise either to the sequences x,' or x n (as the case may be) or to a region external thereto (since the 3' ends of the sequences x and x n to be incorporated in the hybrid molecule are determined by the primers used in the second stage of the PCR reaction (see below)).
  • the other primers for the first stage of PCR reaction are in effect modified PCR primers and comprise a priming sequence (i.e. a sequence which will hybridise to the appropriate x or x' sequence in the manner of a standard PCR primer) attached to a linker sequence.
  • a priming sequence i.e. a sequence which will hybridise to the appropriate x or x' sequence in the manner of a standard PCR primer
  • linker primers are also referred to herein as "linker primers”
  • the linker sequences are such that the primers which hybridise to the 3' ends of any two sequences (x i5 x (i+1) )where i is 1 to (n-1) have linker sequences which are specifically complementary to each other, i.e. these linker sequences will hybridise to each other but not to any other sequences in the reaction mixture.
  • the manner in which the linker sequences function to provide for assembly of the required DNA hybrid molecule will be more fully appreciated from the description given below
  • the linker sequences may for example be comprised of 20 to 30 bases and are ideally such that they do not have any secondary structure (e.g. "hairpins"). It is preferred that the annealing temperature (Tm) of the complementary pairs are substantially the same and is 2-5°C higher than the annealing temperature of the primers to the x and x' sequences.
  • Tm annealing temperature
  • linker primers for the assembly (using PCR reactions employing Taq as the polymerising enzyme) of a hybrid DNA molecule comprised of five sequences x,_ 5 and their respective complements.
  • specific sequence is the priming portion of the linker primer.
  • the "a” represented in bold is an additional adenosine residue incorporated in the primer to take account of the 3' adenosine overhang added by Taq at the end of an extended strand.
  • the linker primers and preferably also the standard PCR primers for the 3' ends of the sequences x,' and x n , are provided in a limiting concentration.
  • a "limiting concentration” is a concentration of primers in a PCR reaction leading to inefficient amplification and such that an increase in concentration results in an increase in product yield.
  • the ratio of primers to single copy template in the limiting PCR reaction may typically be about 1 x 10 6 :1 to about 1 x 10 8 :1 (e.g. about 3 x 10 7 :1).
  • a standard limiting concentration may for example be 40nM. The limiting concentration may however readily be determined empirically for each set of primers used.
  • the first stage PCR reaction may be conducted under the conditions (e.g. polymerase enzyme, nucleotides, buffers, temperature cycling etc.) will be understood by those skilled in the art.
  • the temperature cycling may involve stages of denaturation at 90°C, hybridisation at 60°C, and strand synthesis at 72°C.
  • the polymerase enzyme which is used for the first stage reaction is one formulated so as to be activated by heat (e.g. at 90° to 95°C) so that there are no non-specific hybridisations being extended at low temperature.
  • Heat activated polymerase enzymes are know to those skilled in the art and examples of such enzymes which may be employed in the method of the invention include AmpliTaq Gold (ex Perkin Elmer) and Platinum Taq (ex Gibco BRL).
  • the product of the first stage PCR reaction is treated, prior to the second stage, to prevent the extension of unwanted non-stringent hybridisations between residual primers and the template DNA.
  • This ensures a proper "Hot Start" for the second stage PCR reaction.
  • This treatment may for example comprise an exonuclease digestion involving addition of exonuclease to the first stage reaction mixture followed by incubation of the mixture at 37°C (e.g. for 15 min) and then at 80°C (e.g. for 30 min) so as to remove any single stranded molecules.
  • the first stage reaction mixture is cooled, e.g. at -20°C, to inactivate residual DNA polymerase activity.
  • the second stage reaction there is employed an excess of two PCR primers one of which hybridises to the 3' end of sequence x,' and the other of which hybridises to the 3' end of the sequence x n (and which therefore respectively provide the 5' ends of the sense and anti-sense strands of the intended hybrid molecule).
  • the excess is a concentration of primers such that an increase in concentration does not produce an increase in yield.
  • the "excess" may readily be determined by a person skilled in the art and for a typical reaction might for example be 500nM.
  • Fresh polymerising enzyme is used for the second stage PCR reaction and this is preferably a heat activated polymerase enzyme as described for the first stage reaction.
  • the second stage reaction may be conducted under temperature cycling conditions as described for the first stage reaction.
  • Fig. 1 illustrates a DNA hybrid molecule and a "naturally occurring" DNA molecule from which it is produced
  • Fig. 2 illustrates steps in the conversion of the "naturally occurring" DNA molecule to the hybrid molecule.
  • Figs. 3 to 7 illustrate the results of the Examples.
  • the invention is described by way of example only with reference to the synthesis of a DNA hybrid molecule 1 (see Fig. 1) comprised of exons present in a naturally occurring DNA molecule 2 (see Fig. 1). More particularly, the molecule 2 is shown as being comprised of sense and anti-sense strands 3 and 4 respectively with the former incorporating exons x trench x 2 , x 3 x terrain of interest (e.g. for the purpose of mutation analysis). These sequences x,, x 2 , x 3 x n have their respective complementary sequences x,', x 2 ', x 3 ' x n ' in the anti-sense strand 4 shown and may for example be separated from each other by several hundred bases.
  • the hybrid molecule 1 is illustrated as having sense and anti-sense strands 5 and 6 respectively with the former incorporating the sequences x réelle x 2 , x 3 x n and the latter incorporating sequences x,', x 2 ', x 3 ' x_'.
  • sequences x, and x 2 are connected (reading in the 5' to 3' direction) by the sequence -t-L 12 -a " where a and t represent adenine and thymidine residues respectively and L 12 is a linker sequence (the subscript "12" indicating that the linker is between sequences x, and x 2 .
  • sequences x 2 and x 3 are connected by the sequence -t-L 23 -a and so forth.
  • Fig. 2 illustrates the manner in which molecule 1 is synthesised from molecule 2. More particularly, the synthesis involves a two stage PCR reaction employing heat activated Taq as the polymerising enzyme and in which the first stage utilises limiting concentrations of a plurality of pairs of modified PCR primers, one pair for each of sequences (xicide x,'), (x 2 , x 2 '), (x 3 , x 3 ')
  • the primer pair comprises
  • a first primer having a priming sequence which will specifically hybridise to the 3' region of the "sense sequence" x. and which is connected at its 5'-end to a linker sequence L'. _ 0+1) via an adenine residue ("a");
  • a second primer having a priming sequence which will specifically hybridise to the 3' region of the "antisense sequence" x,' connected at its 5'-end to a linker sequence L , via an adenine residue ("a").
  • the primer pair for sequence (x,, x,') comprises a primer as defined under (i) above (in which the linking sequence is L 12 ) and a conventional PCR primer (PI) specific for the 3' region of sequence x,'.
  • the primer pair for sequences x n , x n ' comprises a primer as defined under (ii) above (in which the linking sequence is L (n . 1) n ) and a conventional PCR (P2) primer specific for the 3' region of sequence x,..
  • linker sequences which form part of the modified PCR primers are such that they do not have any internal secondary structure (e.g. "hairpins") and that two such complementary sequences have an annealing temperature (T m ) which slightly exceeds that of the priming sequence and its complement. Examples of suitable linker sequences have been given above.
  • the "starting" DNA molecule 2 is treated with the sets of primers as described together with a heat activated Taq polymerase (e.g. having an activation temperature of ca 94°C) in an appropriate buffer.
  • a heat activated Taq polymerase e.g. having an activation temperature of ca 94°C
  • all of the primers are present in limiting concentration.
  • the first stage is conducted under conditions of temperature cycling such that there is an initial, relatively high temperature, denaturation step (e.g. at 95°C), followed by a hybridisation step (e.g. at 60°C) followed by a strand synthesis step (e.g. at 72°C).
  • an initial, relatively high temperature, denaturation step e.g. at 95°C
  • a hybridisation step e.g. at 60°C
  • a strand synthesis step e.g. at 72°C.
  • a PCR reaction is effected resulting in the generation of the "short" products (see Fig. 2) in which the 3'- ends of all x and x' sequences (except x, and x n ') are connected to their respective linker sequences via an adenine residue "a" and the 5'-ends of all sequences (except x,' and x n ) are connected to their respective linker sequences via a thymidine residue "t". Furthermore, it will be noted that the 3 '-end of each of the short products has an adenine residue as added by the Taq polymerase.
  • a terminal linking sequence of such longer product so generated may be able to hybridise with a terminal linking sequence of a further "longer" product or of a short product so that further extension is possible to produce fragments of greater length.
  • the generation of the longer products may take place partly in the first stage reaction and partly in the second stage reaction (discussed below) although we do not wish to preclude the possibility that these products are formed wholly in either the first or second stage reaction. It is for this reason that the generation of the "longer” products is illustrated within the box defined by dashed lines and the first and second stages of the PCR reactions are connected by dashed arrows.
  • the reaction mixture is preferably frozen to -20°C to deactivate any residual polymerase activity.
  • flanking primers which define the 5' ends of the sense and anti-sense strands of the intended hybrid molecule are added to the reaction mixture.
  • Fig. 2 illustrates these flanking primers are illustrated as FP1 and FP 2 together with the locations at which they hybridise.
  • further polymerase which is activated only at elevated temperature together with buffers, nucleotides etc.
  • the reaction mixture is then subjected to temperature cycling as previously i.e. denaturation (e.g. at 95°C for 1 min), hybridisation e.g. at 60°C (e.g. for 1 min) and synthesis (e.g. at 72°C for 2 minutes).
  • the polymerase Since the polymerase is only activated at elevated temperature, it is ensured that any sequences which randomly hybridise during the initial heating of the reaction mixture become denatured before the temperature at which the polymerase is activated so that there are substantially no extension reactions resulting from these hybridisations. Put another way, the only hybridisations which occur above the activation temperature of the polymerase are those which are required for generation of the hybrid molecule 1 as explained more fully below.
  • primers p, and p 2 may be external to the sequences x 1 , and x n respectively.
  • a supplementary adenine residue was inserted between the genomic and 5' complementary segments of the self assembling primers in order to accommodate the 3' adenine overhangs added by Taq polymerase to the nascent DNA strand. All primers were checked for homology to Alu repeat sequences using the BLAST analysis program available at http://www.ncbi.nlm.nih.gov/cgi- bin/BLAST/nph-blast. Table 1 gives the sequences and T m s of the 12 primers used in the NF2 exon 6-10 array.
  • DNA was extracted from peripheral blood lymphocytes on an Applied Biosystems 380A DNA extractor.
  • PCR amplification of the self assembling DNA arrays was carried out in two stages. The primary reactions were carried out in 20 ⁇ l volumes using 50ng of genomic DNA, 40nmol.L ⁇ l of primers 1-10 (Table 1), 750 ⁇ mol.L"l of each dNTP, 0.6U Platinum Taq polymerase (GibcoBRL) in a lxPCR buffer comprising 67mM Tris-HCl (pH8.3 @ 25°C), 16.6mM ammonium sulphate, 3.7mM MgCl2 and
  • PCR amplification was carried out on Perkin-Elmer 2400 or 9600 thermal cyclers using the following parameters; initial denaturation 94°C (3 mins), 30 cycles of 94°C (1 min); 60°C (1 min); 72°C (2 mins) followed by a final synthesis of 72°C (10 mins). Immediately on completion of cycling the primary PCR reactions were frozen at -20°C to inactivate residual DNA polymerase activity.
  • Table 1 Primer sequences for amplification of NF2 exon 6-10 self-assembling array. Primers 2 through to 9 are all internal to the self assembling array and contain one of four pairs of complementary 5' termini which are highlighted in italics.
  • the extra adenine nucleotide incorporated to accommodate the 3' terminal adenine residue added by Taq polymerase to the nascent strand is underlined in bold type.
  • the melting temperature (T m ) of the respective genomic or linker portions of each of the primers is also indicated.
  • the secondary reactions were carried out in separate 20 ⁇ l volumes using 2 ⁇ L of the primary PCR, 500nmol.L ⁇ l of primers 11 and 12 (Table 1), 200 ⁇ mol.L ⁇ l of each dNTP, 0.6U Platinum Taq polymerase (GibcoBRL) in a lxPCR buffer comprising 50mM Tris-HCl (pH9.0 @ 25°C), 20mM ammonium sulphate and 1.5mM MgCl2- The thermal cycling conditions were identical to those used for the primary amplifications.
  • the internal primers (11 & 12) were either unlabelled (sequencing and CCM probe DNA) or 5' biotin labelled (CCM test DNA).
  • CCM test DNA 5' biotin labelled (CCM test DNA).
  • secondary PCRs were set up with primary PCRs from normal control DNA, with the addition of TAMRA labelled dCTP (Perkin-Elmer) to a final concentration of 800nmol.L " of secondary PCRs. Otherwise reaction conditions were identical to those described previously for secondary PCRs.
  • each sample was sequenced in both orientations using either primers 11 or 12 with BigDye terminator cycle sequencing kits (Perkin-Elmer, Applied Biosystems)). The manufacturer's protocols were followed with the exception that the annealing temperature for the cycle sequencing reaction was increased from 50°C to 55°C to reflect the high T m of primers 11 and 12. The sequencing reactions were then electrophoresed and collected on an Applied Biosystems 377 fluorescent sequencer using 48cm well to read plates.
  • Heteroduplexes were formed by heating equal quantities of unpurified biotinylated test DNA with unpurified internally TAMRA labelled normal control probe DNA at 94°C for 5 mins followed by annealing at 65°C for 12 hours.
  • the heteroduplexed DNA was purified by electrophoresing each sample through a 1% low gelling temperature agarose gel and cutting out the 1046bp band using a sterile scalpel.
  • the volume of gel slice was estimated by weighing and the gel slice equilibrated for 20 mins in an equal volume of 1 x ⁇ -Agarase buffer comprising lOmM Bis-Tris HC1 (pH6.5) and ImM EDTA.
  • the ⁇ -Agarase buffer was then removed and the gel slice heated at 70°C for 10 mins to liquefy the agarose followed by cooling to 37°C.
  • a further equal volume of 1 x ⁇ -Agarase buffer was added followed by 1U of ⁇ -Agarase I (USB Biochemical). The gel slice was then digested overnight at 37°C.
  • heteroduplexes were then left to complex with the beads for 1 hour at 42°C.
  • the samples were then placed on a magnet to separate the beads and the supernatant carefully removed using a pipette.
  • the beads with bound DNA were resuspended in 20 ⁇ L of a solution of ImM
  • the beads Prior to piperidine cleavage the beads were rinsed once with 50 ⁇ L of TE buffer. Then the beads were resuspended in 5 ⁇ L of a 1M solution of piperidine in deionised formamide to which Genescan 2500 Rox size standard (Perkin-Elmer) and dextran blue loading dye (Sigma) had been added. The samples were heated at 90°C for 30 mins to cleave the modified bases, snap chilled on ice and placed on a magnet to separate the beads from the unbound DNA now in the liquid phase.
  • Genescan 2500 Rox size standard Perkin-Elmer
  • dextran blue loading dye Sigma
  • Figs 4a and 4b show the product of step 1.1.2 sequenced from both termini.
  • Fig 5a shows sequencing in the forward orientation using primer 11.
  • Fig 4b shows sequencing in the reverse orientation using primer 12.
  • the positions of the intron exon boundaries, primer annealing sites and linker sequences are indicated on the electropherograms. The product was seen to comprise the expected exons in the correct orientations. No discernible degradation of sequence was observed across the transitions from one component to the next.
  • step 1.1.2 The procedure of step 1.1.2 was repeated for a range of genomic DNA samples and consistently yielded fragments of the expected size. Reaction yields were generally high ( ⁇ 500ng per lO ⁇ l) with low background (see Fig 5a).
  • products from a series of 7 heterozygotes for NF2 mutations spread throughout four of the five NF2 CR exons were directly sequenced to confirm that the genotype present in genomic DNA was correctly represented in the product.
  • the 7 mutant heterozygotes were as follows nt600-3OG (exon 7), nt676-7T>G (exon 8), nt713delC (exon 8), nt7840T (exon 8), nt855delT (exon 9), nt887delT (exon 10) and nt948G>T + nt949G>T (exon 10).
  • Fig 6 gives example data from four representative mutation heterozygotes.
  • 11 NF2 mutant heterozygotes were then retrospectively screened using a modified fluorescent solid-phase CCM method based on that of Rowley et al, as disclosed in Genomics 30, 574-582. The products were internally labelled using TAMRA dCTP in preference to end labelling. This method helps eliminate false positives resulting from background cleavage.
  • Cleavage of internally labelled products should result in two labelled fragments with a total molecular weight equal to the uncleaved product.
  • Mismatched cytosines were modified using hydroxylamine.
  • mismatched thymines were modified using the potassium permanaganate in preference to osmium tetroxide.
  • nt676-2A>T The mutation not detected by either condition, nt676-2A>T, is predicted to produce heteroduplexes detectable only by potassium permanganate modification (T:T/A:A mismatches). Furthermore, two other mutations producing heteroduplexes with mismatched thymines (nt784C>T and nt903C>T) had undetectable levels of cleavage after potassium permanganate modification. However, both these mutations also produce mismatched cytosines which were detected after hydroxylamine modification. All of the mutations predicted to produce heteroduplexes with mismatched cytosines produced visible cleavage products after hydroxylamine modification.
  • a supplementary unmatched adenine residue was inserted between the genomic and 5' linker segments of the self assembling primers in order to accommodate the 3' adenine overhangs added by Taq polymerase to the nascent DNA strand. All primers were checked for homology to Alu repeat sequences using the BLAST analysis program available at http://www.ncbi.nlm.nih.gov/cgi- bin/BLAST/nph-blast.
  • step 1.1.2 The procedure of step 1.1.2 was repeated for a range of genomic DNA samples and consistently yielded fragments of the expected size. Reaction yields were generally high ( ⁇ 500ng per lO ⁇ l) with low background (see Fig 5b).
  • Genomic sequences of NF2 exons 6-10 amplified by the self assembling array Exonic sequence is indicated by capitals, intronic sequence is in lower case.
  • the annealing sites of primers used in the primary PCR reaction to generate the five self assembling DNA fragments are marked in bold underlined sequence.
  • the annealing sites of the internal primer pair used during the secondary PCR to drive the array assembly are marked in underlined italics.
  • the primary and secondary primers for exon 10 reverse overlap, the region of overlap is marked in bold, underlined italics.
  • AAGCCCAGGC CAGGGAGGAG AAGGCTAGAA

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Plant Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Cette invention est un procédé de production d'une molécule d'ADN hybride permettant de réunir les séquences x1, x2.....xn avec n égal à au moins 3 (cas des séquences donneuses) depuis divers emplacements pour aboutir à une molécule hybride destinée à l'analyse des mutations. Ce procédé de génération de la molécule hybride considérée comporte plusieurs opérations. La première opération consiste notamment (1) à réunir en un seul mélange de réaction, d'une part (a) les séquences x1,x2.......xn et leurs séquences complémentaires x1', x2'.........xn' à assembler pour donner la molécule hybride, et d'autre part, (b) pour chaque paire de séquences complémentaires définie en (a), une paire correspondante d'amorces pour amplification en chaîne par polymérase, chaque paire comportant une séquence d'amorçage et se présentant de façon que les amorces s'hybridant aux extrémités du 3' de chacune des deux séquences (xi, x'(i+1)) comportent des séquences de liaison spécifiquement complémentaires, et ce, pour i valant de 1 à (n-1). La seconde opération consiste (2) à réaliser un premier niveau de réaction d'amplification en chaîne par polymérase dans lequel, celles des amorces qui comportent des séquences de liaison, sont présentes avec des concentrations limitatives. La troisième et dernière opération consiste (3) à effectuer un second niveau de réaction d'amplification en chaîne par polymérase en utilisant une seule paire d'amorces dont l'une fournit l'extrémité du 5' du brin sens et l'autre fournit l'extrémité du 3' du brin antisens de la molécule hybride attendue.
EP99939503A 1998-06-12 1999-06-14 Acides nucleiques Withdrawn EP1086250A2 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9812674.1A GB9812674D0 (en) 1998-06-12 1998-06-12 Nucleic acids
GB9812674 1998-06-12
PCT/GB1999/001691 WO1999064624A2 (fr) 1998-06-12 1999-06-14 Acides nucleiques

Publications (1)

Publication Number Publication Date
EP1086250A2 true EP1086250A2 (fr) 2001-03-28

Family

ID=10833627

Family Applications (1)

Application Number Title Priority Date Filing Date
EP99939503A Withdrawn EP1086250A2 (fr) 1998-06-12 1999-06-14 Acides nucleiques

Country Status (6)

Country Link
EP (1) EP1086250A2 (fr)
JP (1) JP2002517258A (fr)
AU (1) AU5377599A (fr)
CA (1) CA2330252A1 (fr)
GB (1) GB9812674D0 (fr)
WO (1) WO1999064624A2 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2351853A1 (fr) * 2000-06-06 2011-08-03 Life Technologies Corporation Procédé et dispositif de multipléxage de réactions d'amplification
US6605451B1 (en) * 2000-06-06 2003-08-12 Xtrana, Inc. Methods and devices for multiplexing amplification reactions
US7087414B2 (en) 2000-06-06 2006-08-08 Applera Corporation Methods and devices for multiplexing amplification reactions
US8323897B2 (en) 2002-12-04 2012-12-04 Applied Biosystems, Llc Multiplex amplification of polynucleotides
HU229967B1 (hu) 2011-12-20 2015-03-30 Kps Diagnosztika Zrt Eljárás töredezett nukleinsavak szekvenciájának meghatározására

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0613945A2 (fr) * 1993-02-25 1994-09-07 The General Hospital Corporation Merlin, gène suppresseur de tumeurs, et ses utilisations

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5023171A (en) * 1989-08-10 1991-06-11 Mayo Foundation For Medical Education And Research Method for gene splicing by overlap extension using the polymerase chain reaction
WO1992015678A1 (fr) * 1991-03-01 1992-09-17 Stratagene Molecules d'adn dicistroniques produites par reaction en chaine de polymerase et servant a produire des anticorps
ATE361377T1 (de) * 1997-09-29 2007-05-15 Hope City Leistungstarke verknüpfung von nukleinsäuresegmenten

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0613945A2 (fr) * 1993-02-25 1994-09-07 The General Hospital Corporation Merlin, gène suppresseur de tumeurs, et ses utilisations

Also Published As

Publication number Publication date
CA2330252A1 (fr) 1999-12-16
GB9812674D0 (en) 1998-08-12
WO1999064624A2 (fr) 1999-12-16
AU5377599A (en) 1999-12-30
JP2002517258A (ja) 2002-06-18
WO1999064624A3 (fr) 2000-09-14

Similar Documents

Publication Publication Date Title
Pogulis et al. In vitro recombination and mutagenesis by overlap extension PCR
US5759822A (en) Method for suppressing DNA fragment amplification during PCR
US5834252A (en) End-complementary polymerase reaction
JP6374964B2 (ja) 特別なキャプチャープローブ（ｈｅａｔｓｅｑ）を使用したシークエンスキャプチャー法
US5525493A (en) Cloning method and kit
US20030207279A1 (en) Amplification of DNA to produce single-stranded product of defined sequence and length
EP1212449B1 (fr) Amplification de sequences flanquantes a partir d'adn inconnu
WO2007123742A2 (fr) Méthodes et compositions améliorant la fidélité d'assemblage de plusieurs acides nucléiques
US20040091923A1 (en) Linked linear amplification of nucleic acids
EP0854935B1 (fr) Procede de sequencage contigu de genome
CA2001110A1 (fr) Composes et procede pour amplifier et detecter les sequences d'acide nucleique
WO1991018114A1 (fr) Amplification de polynucleotides
EP2785865A1 (fr) Procédé et kit pour la caractérisation d'arn dans une composition
WO2003033718A1 (fr) Synthese d'oligonucleotides sur support solide et assemblage en polynucleotides bicatenaires
Buzdin et al. GREM, a technique for genome-wide isolation and quantitative analysis of promoter active repeats
JP2002535999A (ja) ゲノム分析方法
Moss History and development of molecular biology
US6335184B1 (en) Linked linear amplification of nucleic acids
WO1999064624A2 (fr) Acides nucleiques
EP3237635B1 (fr) Procédé de preparation des fragments de séquencage par "bubble primers"
CN113913493A (zh) 一种靶基因区域快速富集方法
JP4455335B2 (ja) 核酸増幅方法及び一塩基多型検出方法
EP3759243B1 (fr) Procédés et compositions pour l'enrichissement en acides nucléiques
Warshawsky et al. Mapping protein-DNA interactions using in vivo footprinting
JP4681129B2 (ja) 核酸末端領域の非対称的修飾法

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20010110

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): BE CH DE DK ES FI FR GB IE IT LI NL SE

17Q First examination report despatched

Effective date: 20020125

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20040907